Vertex Pharmaceuticals Inc (VRTX)
354.28
+1.97
(+0.56%)
USD |
NASDAQ |
Sep 21, 16:00
352.80
-1.48
(-0.42%)
After-Hours: 07:42
Vertex Pharmaceuticals Cash from Operations (TTM): 4.068B for June 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
June 30, 2023 | 4.068B |
March 31, 2023 | 4.074B |
December 31, 2022 | 4.130B |
September 30, 2022 | 4.046B |
June 30, 2022 | 4.018B |
March 31, 2022 | 2.679B |
December 31, 2021 | 2.644B |
September 30, 2021 | 2.140B |
June 30, 2021 | 2.121B |
March 31, 2021 | 3.359B |
December 31, 2020 | 3.254B |
September 30, 2020 | 3.208B |
June 30, 2020 | 2.635B |
March 31, 2020 | 2.060B |
December 31, 2019 | 1.569B |
September 30, 2019 | 1.438B |
June 30, 2019 | 1.484B |
March 31, 2019 | 1.342B |
December 31, 2018 | 1.270B |
September 30, 2018 | 1.183B |
June 30, 2018 | 971.96M |
March 31, 2018 | 831.91M |
December 31, 2017 | 844.94M |
September 30, 2017 | 762.16M |
June 30, 2017 | 657.72M |
Date | Value |
---|---|
March 31, 2017 | 516.93M |
December 31, 2016 | 236.10M |
September 30, 2016 | 120.52M |
June 30, 2016 | -7.207M |
March 31, 2016 | -158.33M |
December 31, 2015 | -365.43M |
September 30, 2015 | -576.36M |
June 30, 2015 | -601.93M |
March 31, 2015 | -619.59M |
December 31, 2014 | -573.11M |
September 30, 2014 | -371.57M |
June 30, 2014 | -297.64M |
March 31, 2014 | -170.65M |
December 31, 2013 | -60.67M |
September 30, 2013 | -39.87M |
June 30, 2013 | 79.82M |
March 31, 2013 | 199.15M |
December 31, 2012 | 267.84M |
September 30, 2012 | 730.94M |
June 30, 2012 | 667.88M |
March 31, 2012 | 333.28M |
December 31, 2011 | 143.74M |
September 30, 2011 | -526.03M |
June 30, 2011 | -732.92M |
March 31, 2011 | -625.61M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
1.183B
Minimum
Sep 2018
4.130B
Maximum
Dec 2022
2.636B
Average
2.639B
Median
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 5.741B |
Pfizer Inc | 14.56B |
Regeneron Pharmaceuticals Inc | 4.739B |
Axsome Therapeutics Inc | -111.49M |
Moderna Inc | -226.00M |